Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study ID
NCT07253896
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Safety

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Evaluate the objective response rate (ORR) of AK104 combined with chemotherapy and cetuximab or bevacizumab in second-line treatment of MSS type advanced colorectal cancer

Key Dates

First listed
Nov 28, 2025
Start date
Jan 3, 2024
Status verified
Nov 2025
Primary completion
Jan 3, 2026
Completion
Jan 3, 2027

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab
    AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab

Primary Outcome Measure

objective response rate [ Time Frame: the proportion of lung cancer patients participating in clinical research who, after receiving treatment, achieve a significant reduction in tumor volume ]

Central Contacts

Related Studies